Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Moderna Therapeutics

This page shows the latest Moderna Therapeutics news and features for those working in and with pharma, biotech and healthcare.

BMS to explore new options for its immuno-oncology drug Opdivo

BMS to explore new options for its immuno-oncology drug Opdivo

The company will work with PsiOxus Therapeutics to evaluate the safety and efficacy of the Oxford, UK biotech's enadenotucirev in combination with Opdivo for the treatment of a range of ... Like BMS, Merck &Co has also moved to extend the reach of its

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Deal Watch September 2016. Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... Moderna Therapeutics has received $8m of the grant to fund early-stage trials of the vaccine and plans to submit an

  • Deal Watch June 2016 Deal Watch June 2016

    Back to the immuno-oncology theme, near the end of June Merck &Co signed a collaboration agreement with Moderna Therapeutics to use Moderna's mRNA technology to develop personalised cancer vaccines. ... licence. 230. Moderna Therapeutics/ Merck &Co.

  • Deal Watch October 2015 Deal Watch October 2015

    Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co, ... This is Moderna's fourth venture in what it calls

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290. ... 144. Moderna Therapeutics/ Alexion Pharmaceuticals. Exclusive discovery and development. Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options.

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Commercialisation. Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast . ... Moderna Therapeutics / DARPA. R&D grant. mRNA therapeutics for biodefence targets (discovery).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Tony de Fougerolles joins Evox Therapeutics as CEO Tony de Fougerolles joins Evox Therapeutics as CEO

    Oxford, UK-based Evox Therapeutics has appointed its new chief executive officer in the form of Tony de Fougerolles. ... Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.

  • Medicxi appoints former GSK chair Moncef Slaoui Medicxi appoints former GSK chair Moncef Slaoui

    Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.

  • MIT chief financial officer joins Moderna Therapeutics MIT chief financial officer joins Moderna Therapeutics

    MIT chief financial officer joins Moderna Therapeutics. Israel Ruiz to serve as audit committee chair on its board of directors. ... US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee

  • PureTech Health appoints chief scientific officer PureTech Health appoints chief scientific officer

    Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.

  • Dr Michael Watson appointed as president of Valera Dr Michael Watson appointed as president of Valera

    Dr Michael Watson appointed as president of Valera. Former Sanofi Pasteur policy head joins Moderna Therapeutics firm. ... Valera, one of Moderna Therapeutics' venture companies, has appointed Dr Michael Watson as its new president.

More from appointments
Approximately 3 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Quick links

Infographics

Multimedia